MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
ordinary shares, net of...
$5,432K
Net cash provided by
financing activities
$5,432K
Net (decrease) /
increase in cash, cash...
-$2,029K
Canceled cashflow
$5,432K
Accrued expenses
$1,343K
Other
-$880K
Adjustments to fair value of
derivatives
-$673K
Interest on notes -
non-cash-Promissory Note
$562K
Amortization of intangible
asset
$349K
Share-based compensation
expense
$53K
Depreciation
$6K
Net cash used in
operating activities
-$7,447K
Canceled cashflow
$3,866K
Net cash (used in) /
provided by investing...
-$12K
Effect of exchange
rates on cash and cash...
-$2K
Net loss
-$8,979K
Prepaid expenses and
other current assets
$984K
Accounts payable
-$612K
Accounts receivable
$448K
Inventory
$201K
Income taxes
-$89K
Purchases of property and
equipment
$12K
Back
Back
Cash Flow
source: myfinsight.com
Iterum Therapeutics plc (ITRM)
Iterum Therapeutics plc (ITRM)